Wearable biosensors to be worth US$25bn by 2030: Lux Research

Med Learning AdobeStock 427714968Biosensors offer tremendous promise as convenient, easy-to-use, and low-cost solutions to monitor underlying physiological conditions compared to other incumbent diagnostic techniques

This will lead to an increase in applications for biosensors, such as vital signs monitoring, metabolism monitoring, biomarker detection, and disease diagnosis.

However, many challenges related to precision, accuracy, and commercialisation, and deployment need to be overcome before biosensors can gain widespread adoption in consumer health and wellness, according to a new analysis from Lux Research, a leading provider of market research and advisory services focused on emerging technologies.

Lux’s new report, Emerging Biosensor Technologies: Landscape and Market Forecast, outlines recent innovations in biosensor technologies, discusses challenges that stakeholders will need to overcome, and provides an outlook for the technology and business of biosensors. In this report, Lux identifies and focuses on five health conditions that significantly impact daily life for consumers, thereby offering opportunities for businesses to develop consumer-centric solutions for diagnosis, monitoring and prevention. These include: cardiovascular disease, diabetes, stress, hydration and sleep disturbance.

Although active and continuous monitoring solutions are available for all five leading health conditions, gaps remain that point to the opportunity to develop innovative solutions. Incumbent testing and diagnostic technologies are often expensive, bulky, and uncomfortable for long-term or on-demand monitoring applications. In contrast, wearable electronics offer convenient biosensing capabilities and allow consumers to monitor their health continuously and derive insights.

“Patients today face enormous financial and psychological burdens because of rapidly rising healthcare costs. The rising prevalence of various health conditions in the population is placing tremendous pressure on already-overburdened healthcare systems,” states Lisheng Gao, PhD, an analyst at Lux Research and lead author of the report. “On the flip side, this offers substantial business opportunities, particularly in the area of consumer-centric healthcare technologies.”

With a growing population suffering from various health conditions and increasing awareness around the importance of monitoring health conditions, the wearable biosensor device market will proliferate, with favourable regulations and insurance policies further catalyzing growth. Ultimately, Lux forecasts that, by 2030, the total market for biosensor devices for the five health conditions in the EU, APAC, and North America together will be around US$25bn, with a CAGR of 23%.

Alain Charles Publishing, University House, 11-13 Lower Grosvenor Place, London, SW1W 0EX, UK
T: +44 20 7834 7676, F: +44 20 7973 0076, W: www.alaincharles.com

twn Are you sure that you want to switch to desktop version?